Chong Kun Dang Pharmaceutical Corp. 185750

KRX · South Korea · Health Technology

KRW 64,900.00-300.00 (-0.46%)

Market open· Oct 2, 2026, 2:53 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Chong Kun Dang Pharmaceutical Corp. 185750

KRX · South Korea · Health Technology

KRW 64,900.00-300.00 (-0.46%)

Market open· Oct 2, 2026, 2:53 AM UTC· KRW · Data may be delayed

Company news

Yahoo FinanceAug 19, 2026

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.